Clinical assessment of bronchodilator drugs delivered by aerosol

Shenfield, Gillian M.; Paterson, J. W.

doi:10.1136/thx.28.2.124

Cited by 56 publications

(15 citation statements)

References 10 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies in patients with chronic, stable airways obstruction have shown a similar dose-response pattern to large doses of /3-adrenoceptor agonist by inhalation (Svedmyr, Malmberg & Thiringer, 1972;Martin et al, 1977;. Shenfield & Paterson (1973) (Jenne, Wyze, Rood & MacDonald, 1972;Mitenko & Ogilvie, 1973;Levy & Koysooko, 1975;Ogilvie, 1978;Weinberger, 1978). This work suggests that salbutamol by inhalation possesses a greater potential therapeutic range with a wider margin of safety than oral theophylline.…”

supporting

confidence: 55%

“…However, for an accurate assessment of relative potency, the relationship of the dose of the drugs to their dose-response curves must be known. The value of establishing dose-response curves when comparing the bronchodilator.potencies of drugs is well established (Shenfield & Paterson, 1973;Marlin, Hartnett & Berend, 1977;Marlin, Bush & Berend, 1978 (I979), 8 The purpose of the salbutamol dose-response was to establish if possible the maximal degree of bronchodilator reversibility of airways obstruction attainable in these patients, in order to determine the relative potency of theophylline. However, it appeared that sixteen inhalations (1600 jig) of salbutamol may still have been submaximal.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Dose‐titration comparison of inhaled salbutamol and oral theophylline in asthma.

Marlin¹,

Harris²,

Klumpp³

et al. 1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

supporting

confidence: 55%

mentioning

confidence: 99%

Dose‐titration comparison of inhaled salbutamol and oral theophylline in asthma.

Marlin¹,

Harris²,

Klumpp³

et al. 1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…They also reported no significant differences in maximal FEV1 change for different dose levels of fenoterol (1 and 2 mg), salbutamol (1 and 2 mg) and orciprenaline (2.5 and 5 mg). Shenfield & Paterson (1973) The study was double-blind and each test commenced between 09.00 and 10.00 h. After a 15 min rest in the laboratory, baseline FEV1 and VC were measured using a water filled bell-type spirometer (Goddard expirograph). Three forced and three slow expiratory manoeuvres from total lung capacity to residual volume were performed and the highest of each set were taken as the FEV1 and VC respectively.…”

Section: Introductionmentioning

confidence: 99%

Cross‐over study of the efficacy of four beta 2‐sympathomimetic bronchodilator aerosols

Madsen¹,

Tandon²,

Paterson³

1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Bronchodilator efficacy of four beta 2‐sympathomimetic aerosols, fenoterol, orciprenaline, salbutamol and terbutaline has been compared in nine patients with chronic stable reversible airways obstruction using a double‐blind placebo controlled cross‐over design. Two puffs of each agent were given on two separate occasions to each of the patients and the forced expiratory volume in one second (FEV1) and the vital capacity (VC) were measured before and 30, 90, 150 and 210 min after administration. 2 Multivariate analysis of the data at 30 min showed FEV1 and VC in these patients to be so highly correlated that they could be considered as a single variable. 3 When absolute change in VC at 30 min was used as the response criterion, efficacy of the four drugs was significantly better than placebo (P < 0.01). It was not possible to rank all four drugs in order of effectiveness; fenoterol and salbutamol were significantly better than terbutaline and orciprenaline (P < 0.01) but this was complicated by a significant interaction effect between drugs and patients (P < 0.01). 4 Similar results were obtained when absolute and relative changes in FEV1 and VC and area under the curve were used as response variables. 5 The study demonstrates that important individual differences in patient response may be concealed if only average drug effects are considered.

show abstract

“…Paterson [7] comments that although isoprénaline is not pharmacologically selective, between /?,-and ^¡¡-receptors, its therapeutic effect is selective when given by inhalation and Shenjield and Paterson [8] found no change in pulse rate after a single dose of 0.16 mg or a cumulative dose of 0.48 mg isoprénaline given to patients by inhalation. Earlier, Feinmann and Hume [9] in a dose-titration study showed that 90°/o of a representative group of asthmatic patients obtained the maximum possible bronchodilation after in halation of 0.24 mg or less of isoprénaline and that at these doses pulse rate changes were minimal.…”

Section: The Development Of Selective Sympathomimetic Agentsmentioning

confidence: 99%

A Brief Review of Sympathomimetic Bronchodilators and a Description of a New Selective Agent, Rimiterol Hydrobromide

Muittari¹

1978

Respiration

View full text Add to dashboard Cite

The development of β₂-specific sympathomimetic bronchodilators (rimiterol, salbutamol, terbutaline) has made the basic treatment of asthmatic patients more safe and effective. Despite that, the asthmatics should be under careful control and all patients should be taught the correct way to use their bronchodilator aerosols. If a sympathomimetic drug has lost its effectiveness, the patient should be able to have easy contact to the treating physician or outpatient department.

show abstract

Clinical assessment of bronchodilator drugs delivered by aerosol

Cited by 56 publications

References 10 publications

Dose‐titration comparison of inhaled salbutamol and oral theophylline in asthma.

Dose‐titration comparison of inhaled salbutamol and oral theophylline in asthma.

Cross‐over study of the efficacy of four beta 2‐sympathomimetic bronchodilator aerosols

A Brief Review of Sympathomimetic Bronchodilators and a Description of a New Selective Agent, Rimiterol Hydrobromide

Contact Info

Product

Resources

About